331 related articles for article (PubMed ID: 30397147)
1. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
[TBL] [Abstract][Full Text] [Related]
2. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
4. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
5. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
6. Chemoenzymatic Defucosylation of Therapeutic Antibodies for Enhanced Effector Functions Using Bacterial α-Fucosidases.
Li C; Li T; Wang LX
Methods Mol Biol; 2018; 1827():367-380. PubMed ID: 30196507
[TBL] [Abstract][Full Text] [Related]
7. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
8. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
9. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.
Mimura Y; Ashton PR; Takahashi N; Harvey DJ; Jefferis R
J Immunol Methods; 2007 Sep; 326(1-2):116-26. PubMed ID: 17714731
[TBL] [Abstract][Full Text] [Related]
10. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
11. Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins.
Yang Q; Wang LX
Methods Enzymol; 2017; 597():265-281. PubMed ID: 28935106
[TBL] [Abstract][Full Text] [Related]
12. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.
Liu CP; Tsai TI; Cheng T; Shivatare VS; Wu CY; Wu CY; Wong CH
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):720-725. PubMed ID: 29311294
[TBL] [Abstract][Full Text] [Related]
13. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
Giddens JP; Wang LX
Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
[TBL] [Abstract][Full Text] [Related]
14. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
15. Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation.
Castilho A; Gruber C; Thader A; Oostenbrink C; Pechlaner M; Steinkellner H; Altmann F
MAbs; 2015; 7(5):863-70. PubMed ID: 26067753
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of glycan ratio of Chinese hamster ovary cell-cetuximab antigen-binding segment via rapid enzyme digestion with endo-
Cheng Q; Jia D; Zhang B; Xu J; Shao Z; Huang Y; Zou X
Se Pu; 2022 Feb; 40(2):175-181. PubMed ID: 35080164
[TBL] [Abstract][Full Text] [Related]
17. The enzymatic removal of immunoglobulin variable domain glycans by different glycosidases.
van de Bovenkamp FS; Derksen NIL; Ooijevaar-de Heer P; Rispens T
J Immunol Methods; 2019 Apr; 467():58-62. PubMed ID: 30742813
[TBL] [Abstract][Full Text] [Related]
18. EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans.
Sjögren J; Cosgrave EF; Allhorn M; Nordgren M; Björk S; Olsson F; Fredriksson S; Collin M
Glycobiology; 2015 Oct; 25(10):1053-63. PubMed ID: 26156869
[TBL] [Abstract][Full Text] [Related]
19. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
Popp O; Moser S; Zielonka J; Rüger P; Hansen S; Plöttner O
MAbs; 2018; 10(2):290-303. PubMed ID: 29173063
[TBL] [Abstract][Full Text] [Related]
20. Generation and Comparative Kinetic Analysis of New Glycosynthase Mutants from Streptococcus pyogenes Endoglycosidases for Antibody Glycoengineering.
Tong X; Li T; Li C; Wang LX
Biochemistry; 2018 Sep; 57(35):5239-5246. PubMed ID: 30102520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
